Gene · 5933
RBL1: RB transcriptional corepressor like 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RBL1: RB transcriptional corepressor like 1. Genes, record 5933. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5933
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28749 | Retinoblastoma-like protein 1 | 1,068 | 10 | Ensembl, GeneID, HGNC |
Source UniProt
Patents30
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4641201 A2 | 2025-10-29 | 9592 | P28749 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3680 | P28749 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3680 | P28749 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9592 | P28749 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8178 | P28749 | Espacenet |
| US 11708396 B2 | 2023-07-25 | 2332 | P28749 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 72903 | P28749 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 175874 | P28749 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9418 | P28749 | Espacenet |
| US 10501513 B2 | 2019-12-10 | 8178 | P28749 | Espacenet |
1 to 10 of 30
See all 30 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,909
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RBL1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 15 | 2025 |
| T32CA009302 | Leveraging innovative technologies in basic and clinical cancer research | 13 | 2025 |
| P01CA022443 | Molecular Biology and Genetics of Human Tumor Viruses | 12 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P01CA019014 | Viral Oncogenesis, Latency, and Replication | 7 | 2025 |
| P50CA168504 | Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer | 7 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 6 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 5 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,909Source NIH's project files
See all 1,909 nih grantsPapers2,741
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Predicting gene compensation in disease with graph embedding techniques. | Artif Intell Med | 2026 | 42632343 | PubTator, text mining | PubMed |
| Fueling or Fighting Cancer? The Thermogenic Paradox of Brown Adipose Tissue. | Curr Obes Rep | 2026 | 41848823 | PubTator, text mining | PubMed |
| Exploiting cellular senescence in hematologic malignancies. | Transl Oncol | 2026 | 41844438 | PubTator, text mining | PubMed |
| Transcriptomics in Venous Leg Ulcers (VLU): A Systematic Review. | Wound Repair Regen | 2026 | 41787822 | PubTator, text mining | PubMed |
| The paradox of cellular senescence in prostate cancer: from tumor suppression to tumor promotion. | Front Oncol | 2026 | 41783438 | PubTator, text mining | PubMed |
| Beyond Oncogenes: Selectively Targeting Whole-Tumor Cell Growth Regulation. | Drug Des Devel Ther | 2026 | 41769264 | PubTator, text mining | PubMed |
| Mechanisms of the Antiproliferative Effects of SIRT6 Inhibition in Melanoma: A Multi-Omics Analysis. | Cancers (Basel) | 2026 | 41749843 | PubTator, text mining | PubMed |
| Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer. | Research (Wash D C) | 2026 | 41743623 | PubTator, text mining | PubMed |
| Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance. | J Natl Cancer Cent | 2026 | 41738032 | PubTator, text mining | PubMed |
| Targeted therapy for liver cancer: Current status and future directions. | Bioimpacts | 2025 | 41716515 | PubTator, text mining | PubMed |
1 to 10 of 2,741
See all 2,741 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5933
GET https://conductscience.org/api/genes/v1/5933/patents?page=2